Cipla’s New York plant gets FDA no-action classification
FDA gave Cipla’s InvaGen plant in Hauppauge a No Action Indicated classification after its October 2026 inspection, easing regulatory uncertainty without approving any drug or product.
TAG E-9124 · 560 words on the filing

Summary of findings
- USFDA classified InvaGen’s Hauppauge plant No Action Indicated on November 17, 2026.
- The regulatory inspection ran from October 19 through October 22, 2026.
- Cipla disclosed completion of the inspection to stock exchanges on October 23, 2026.
- Cipla shares traded near ₹1,390 on November 18, 2026, about 0.14% above the prior NSE close of ₹1,388.
- Q2 FY27 revenue from operations was ₹7,404 crore; EBITDA was ₹1,388 crore and profit after tax was ₹878 crore.
By Daniel Okafor
Cipla’s InvaGen Pharmaceuticals plant in Hauppauge, Long Island, received a “No Action Indicated” classification from the US Food and Drug Administration (USFDA) on November 17, 2026, after a four-day inspection that identified no conditions requiring regulatory action.
What did the FDA’s NAI classification mean?
Cipla disclosed the final classification to stock exchanges on November 17, after USFDA inspected InvaGen Pharmaceuticals Inc., its wholly owned subsidiary, from October 19 through October 22, 2026. The company had already reported completion of that inspection to exchanges on October 23.
No Action Indicated (NAI) means USFDA did not identify conditions requiring regulatory action when it closed the inspection. Cipla’s disclosure called the outcome favorable for its US manufacturing operations and said it provided regulatory clarity. It does not, however, represent approval of any new drug or product.
In plain terms: the inspection closed without a regulatory action requirement.
What changed in Cipla’s disclosure timeline?
- October 19-22, 2026: USFDA inspected InvaGen’s manufacturing facility in Hauppauge.
- October 23, 2026: Cipla told stock exchanges that the inspection was complete.
- November 17, 2026: USFDA communicated the final NAI classification, and Cipla disclosed the outcome to exchanges.
The sequence matters because the October 23 filing covered only the end of the site visit. The November 17 disclosure supplied the regulatory conclusion and closed that reporting sequence.
The filing record now contains an outcome, not merely an inspection event.
How did the shares respond?
Cipla shares traded at approximately ₹1,390 on Wednesday, November 18, about ₹2 or 0.14% above the previous NSE close of ₹1,388 from November 17. The stock initially traded near ₹1,390, slipped toward ₹1,382.50 during morning trading, then recovered toward ₹1,390.
The supplied chart ran to roughly 9:53 AM IST and did not display an exact last-traded price or timestamp, so the quoted prices are approximate. The announcement’s direct contribution to the marginal share-price increase remains unconfirmed.
The market response was positive but too small to attribute confidently to the FDA notice.
What do the latest financials show?
Cipla announced its latest quarterly results on October 27, providing financial context around the regulatory disclosure.
- Consolidated revenue from operations: ₹7,404 crore in Q2 FY27, against ₹7,589 crore in the corresponding quarter last year.
- EBITDA: ₹1,388 crore.
- Profit after tax: ₹878 crore.
The disclosure gave no prior-year comparatives for EBITDA or profit after tax. It also did not attach a revenue or earnings contribution to the NAI classification, leaving the inspection result operationally positive but financially unquantified.
Operationally positive, financially unquantified: the inspection does not become an earnings catalyst without further commercial disclosure.
Where does InvaGen fit within Cipla?
Cipla Limited is a Mumbai-based pharmaceutical company that develops, manufactures and markets medicines across multiple therapeutic categories. It operates in India, North America, South Africa and other international markets. Its portfolio spans respiratory medicines, anti-infectives, cardiovascular treatments and other pharmaceutical products.
Cipla owns InvaGen Pharmaceuticals Inc. outright as its US subsidiary. The Hauppauge inspection therefore concerns a wholly owned US manufacturing operation within Cipla’s existing international network. No site-level sales, product mix or capacity figures accompanied the announcement, so readers should not infer them from the NAI classification.
InvaGen is a US manufacturing node whose regulatory status has now been clarified.
via nseindia.in (Original)
More from Daniel Okafor
Show full bio
Correspondent covering technology and product news in global pharmaceutical industry at PharmInsider.
5 articles
Linked filings
- P-1559
- E-4696
- P-6323
- E-6700
- K-7275